risperidone has been researched along with Autism Spectrum Disorder in 62 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Autism Spectrum Disorder: Wide continuum of associated cognitive and neurobehavioral disorders, including, but not limited to, three core-defining features: impairments in socialization, impairments in verbal and nonverbal communication, and restricted and repetitive patterns of behaviors. (from DSM-V)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the effectiveness and safety of risperidone and aripiprazole in children with autism spectrum disorder (ASD)." | 9.41 | Risperidone and aripiprazole for autism spectrum disorder in children: an overview of systematic reviews. ( Chen, MH; Escobar Liquitay, CM; Fieiras, C; Franco, JVA; Madrid, E; Meza, N; Rojas, V, 2023) |
| "This study aimed at investigating the efficacy and tolerability of l-carnosine as an add-on to risperidone in the management of children with autism." | 9.27 | l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. ( Afarideh, M; Akhondzadeh, S; Ghajar, A; Hajizadeh-Zaker, R; Mesgarpour, B; Mohammadi, MR, 2018) |
| "Memantine showed safety in reducing acute symptoms of anxiety and other symptoms encountered in pediatric patients with autism spectrum disorders." | 9.22 | Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis. ( Abdelgalil, MS; Ali, MM; Benmelouka, AY; Brimo Alsaman, MZ; Elgendy, AMN; Elnaiem, W; Mogheeth, A; Yousof, SM, 2022) |
| "Risperidone is approved for the treatment of serious behavioral problems in children with autism spectrum disorder (ASD)." | 9.22 | No Apparent Cardiac Conduction Effects of Acute Treatment with Risperidone in Children with Autism Spectrum Disorder. ( Aman, MG; Arnold, LE; Carroll, D; Kelleman, M; Levi, D; McCracken, C; McCracken, JT; McDougle, CJ; Morrissey, J; Scahill, L; Snyder, C; Tierney, E; Vitiello, B; Vo, LC, 2016) |
| "Rapid weight gain with risperidone treatment may promote the cascade of biochemical indices associated with insulin resistance and metabolic syndrome." | 9.22 | Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. ( Aman, MG; Arnold, LE; Boorin, SJ; Caprio, S; Challa, SA; Deng, Y; Dziura, J; Jeon, S; McCracken, JT; McDougle, CJ; Nicol, G; Scahill, L; Vitiello, B, 2016) |
| "Risperidone is the first antipsychotic to be approved by Food and Drug Administration (FDA) for treating autism spectrum disorder (ASD)." | 8.31 | The comparative effectiveness of metformin and risperidone in a rat model of valproic acid-induced autism, Potential role for enhanced autophagy. ( Ashour, RH; Atia, AA; Rahman, KM; Ramadan, NM; Zaki, MM, 2023) |
| " Here, authors report on a challenging case of low-functioning ASD child with comorbid ARFID and misophonia that responded favorably to a low-dose risperidone." | 8.12 | Low-Dose Risperidone for an Autistic Child with Comorbid ARFID and Misophonia. ( Abuzeid, MY; Al-Humoud, AM; Elsori, D; Naguy, A; Pridmore, S; Singh, A, 2022) |
| "Risperidone and aripiprazole, commonly used antipsychotics in children with autism spectrum disorder (ASD), have previously been associated with elevated fracture risk in other populations." | 8.02 | Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders. ( de Vries, F; Houghton, R; Law, K; Liu, Y; van den Bergh, J, 2021) |
| "This study demonstrated that there was no significant difference in weight gain between risperidone and aripiprazole users during the first year of treatment." | 7.91 | No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months. ( Beex-Oosterhuis, MM; Dieleman, HG; Eussen, MLJM; Schoemakers, RJ; van Kesteren, C; van Rosmalen, J, 2019) |
| "The aim of this study was to investigate the association of drug-metabolizing enzyme and transporter (DMET) polymorphisms with the risperidone-induced prolactin response using an overlapping gene model between serum prolactin level and hyperprolactinemia in autism spectrum disorder (ASD) patients." | 7.88 | UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder. ( Chamnanphon, M; Hongkaew, Y; Limsila, P; Medhasi, S; Ngamsamut, N; Pasomsub, E; Puangpetch, A; Sukasem, C; Suthisisang, C; Vanwong, N; Wilffert, B, 2018) |
| "The purpose of this study was to explore the association of genetic polymorphism of genes related to pharmacokinetics or pharmacodynamics with insulin resistance in children and adolescents with autism spectrum disorder (ASD) and treated with risperidone." | 7.88 | Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder. ( Chamkrachangpada, B; Hongkaew, Y; Limsila, P; Ngamsamut, N; Nuntamool, N; Puangpetch, A; Srisawasdi, P; Sukasem, C; Vanwong, N, 2018) |
| "All 97 autism spectrum disorder patients included in this study had been receiving risperidone at least for 1 month." | 7.85 | Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder. ( Chamnanphon, M; Hongkaew, Y; Limsila, P; Medhasi, S; Ngamsamut, N; Puangpetch, A; Sukasem, C; Tan-Kam, T; Vanwong, N, 2017) |
| "We present a case of a 12-year-old Moroccan boy diagnosed with autism spectrum disorder who developed priapism while on an existing regimen of risperidone, and we report the treatment decisions that followed." | 7.83 | Risperidone-induced priapism in an autistic child: a case report. ( Aabbassi, B; Asri, F; Benali, A, 2016) |
| "DRD2 Taq1A A2A2 polymorphisms may play a significant role in the hyperprolactinemia- associated with risperidone treatment in children and adolescent with autism spectrum disorder." | 7.83 | Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders. ( Chamkrachchangpada, B; Chamnanphon, M; Hongkaew, Y; Limsila, P; Ngamsamut, N; Puangpetch, A; Sinrachatanant, A; Sukasem, C; Vanwong, N, 2016) |
| "Sulforaphane was administered at a daily dose of 50 μmol (≤45 kg) or 100 μmol (>45 kg)." | 6.94 | Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial. ( Akhondzadeh, S; Amirimoghaddam-Yazdi, Z; Moghaddam, HS; Mohammadi, MR; Momtazmanesh, S, 2020) |
| " Food and Drug Administration to treat "irritability" in children and adolescents with autism spectrum disorder, in combination with another drug with respect to experimental design, assessment techniques, drug co-administered, reported effects, and participant characteristics." | 6.55 | Risperidone in combination with other drugs: Experimental research in individuals with autism spectrum disorder. ( Curiel, H; Li, A; MacNeill, B; Poling, A, 2017) |
| "Risperidone (RIS) is a widely used atypical antipsychotic drug." | 5.43 | Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9-Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders. ( Hongkaew, Y; Limsila, P; Nakorn, CN; Ngamsamut, N; Nuntamool, N; Prommas, S; Puangpetch, A; Sukasem, C; Vanwong, N, 2016) |
| "These results suggest that hyperprolactinaemia may develop during risperidone treatment." | 5.43 | 9-Hydroxyrisperidone-Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder. ( Chamkrachangpada, B; Hongkaew, Y; Limsila, P; Ngamsamut, N; Puangpetch, A; Srisawasdi, P; Sukasem, C; Tan-Khum, T; Vanwong, N, 2016) |
| "This study aimed at investigating the efficacy and tolerability of l-carnosine as an add-on to risperidone in the management of children with autism." | 5.27 | l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. ( Afarideh, M; Akhondzadeh, S; Ghajar, A; Hajizadeh-Zaker, R; Mesgarpour, B; Mohammadi, MR, 2018) |
| "Memantine showed safety in reducing acute symptoms of anxiety and other symptoms encountered in pediatric patients with autism spectrum disorders." | 5.22 | Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis. ( Abdelgalil, MS; Ali, MM; Benmelouka, AY; Brimo Alsaman, MZ; Elgendy, AMN; Elnaiem, W; Mogheeth, A; Yousof, SM, 2022) |
| "Rapid weight gain with risperidone treatment may promote the cascade of biochemical indices associated with insulin resistance and metabolic syndrome." | 5.22 | Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. ( Aman, MG; Arnold, LE; Boorin, SJ; Caprio, S; Challa, SA; Deng, Y; Dziura, J; Jeon, S; McCracken, JT; McDougle, CJ; Nicol, G; Scahill, L; Vitiello, B, 2016) |
| "The purpose of this manuscript is to review the evidence generated by clinical trials of pharmaceuticals in autism spectrum disorder (ASD), describe challenges in the conduct of such trials, and discuss future directions RECENT FINDINGS: Clinical trials in ASD have produced several compounds to adequately support the pharmacological treatment of associated symptom domains: attention deficit hyperactivity disorder (methylphenidate, atomoxetine, and alpha agonists), irritability/aggression (risperidone and aripiprazole), sleep (melatonin), and weight gain associated with atypical antipsychotic use (metformin)." | 4.98 | Clinical trials in autism spectrum disorder: evidence, challenges and future directions. ( Anagnostou, E, 2018) |
| "Risperidone is the first antipsychotic to be approved by Food and Drug Administration (FDA) for treating autism spectrum disorder (ASD)." | 4.31 | The comparative effectiveness of metformin and risperidone in a rat model of valproic acid-induced autism, Potential role for enhanced autophagy. ( Ashour, RH; Atia, AA; Rahman, KM; Ramadan, NM; Zaki, MM, 2023) |
| " Here, authors report on a challenging case of low-functioning ASD child with comorbid ARFID and misophonia that responded favorably to a low-dose risperidone." | 4.12 | Low-Dose Risperidone for an Autistic Child with Comorbid ARFID and Misophonia. ( Abuzeid, MY; Al-Humoud, AM; Elsori, D; Naguy, A; Pridmore, S; Singh, A, 2022) |
| "Risperidone and aripiprazole, commonly used antipsychotics in children with autism spectrum disorder (ASD), have previously been associated with elevated fracture risk in other populations." | 4.02 | Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders. ( de Vries, F; Houghton, R; Law, K; Liu, Y; van den Bergh, J, 2021) |
| "This study demonstrated that there was no significant difference in weight gain between risperidone and aripiprazole users during the first year of treatment." | 3.91 | No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months. ( Beex-Oosterhuis, MM; Dieleman, HG; Eussen, MLJM; Schoemakers, RJ; van Kesteren, C; van Rosmalen, J, 2019) |
| "The aim of this study was to investigate the association of drug-metabolizing enzyme and transporter (DMET) polymorphisms with the risperidone-induced prolactin response using an overlapping gene model between serum prolactin level and hyperprolactinemia in autism spectrum disorder (ASD) patients." | 3.88 | UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder. ( Chamnanphon, M; Hongkaew, Y; Limsila, P; Medhasi, S; Ngamsamut, N; Pasomsub, E; Puangpetch, A; Sukasem, C; Suthisisang, C; Vanwong, N; Wilffert, B, 2018) |
| "The purpose of this study was to explore the association of genetic polymorphism of genes related to pharmacokinetics or pharmacodynamics with insulin resistance in children and adolescents with autism spectrum disorder (ASD) and treated with risperidone." | 3.88 | Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder. ( Chamkrachangpada, B; Hongkaew, Y; Limsila, P; Ngamsamut, N; Nuntamool, N; Puangpetch, A; Srisawasdi, P; Sukasem, C; Vanwong, N, 2018) |
| "Rodents exposed prenatally to valproic acid (VPA) exhibit autism spectrum disorder (ASD)-like behavioral abnormalities." | 3.85 | Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice. ( Ago, Y; Hara, Y; Hasebe, S; Hashimoto, H; Kawase, H; Matsuda, T; Nakazawa, T; Takuma, K; Tanabe, W; Taruta, A; Tsukada, S, 2017) |
| "All 97 autism spectrum disorder patients included in this study had been receiving risperidone at least for 1 month." | 3.85 | Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder. ( Chamnanphon, M; Hongkaew, Y; Limsila, P; Medhasi, S; Ngamsamut, N; Puangpetch, A; Sukasem, C; Tan-Kam, T; Vanwong, N, 2017) |
| "We present a case of a 12-year-old Moroccan boy diagnosed with autism spectrum disorder who developed priapism while on an existing regimen of risperidone, and we report the treatment decisions that followed." | 3.83 | Risperidone-induced priapism in an autistic child: a case report. ( Aabbassi, B; Asri, F; Benali, A, 2016) |
| "Risperidone-related weight gain is associated with a reduction in body iron reserves, which appears to improve with weight loss following risperidone discontinuation." | 3.81 | Iron homeostasis during risperidone treatment in children and adolescents. ( Aman, M; Arnold, LE; Calarge, CA; Del Castillo, N; McCracken, JT; McDougle, CJ; Scahill, L; Ziegler, EE, 2015) |
| "Patients were assessed using childhood autism rating scale (CARS), Gilliam autism rating scale-second edition (GARS-II), and clinical global impression (CGI) at the baseline, as well as 6 and 12 months after intervention." | 3.01 | Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial. ( Fayyazi Bordbar, MR; Ghasemi, A; Moharari, F; Nahidi, M; Pouryousof, HR; Sharifzadeh, N; Soltanifar, A; Talaei, A; Tavakol Afshari, J; Ziaee, M, 2021) |
| "The etiology of autism is hypothesized to include both biological and environmental factors (Watts, 2008)." | 3.01 | Autism Spectrum Disorder and Complementary-Integrative Medicine. ( Arnold, LE; Hendren, RL; Simkin, DR; Vandana, P, 2023) |
| "Sulforaphane was administered at a daily dose of 50 μmol (≤45 kg) or 100 μmol (>45 kg)." | 2.94 | Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial. ( Akhondzadeh, S; Amirimoghaddam-Yazdi, Z; Moghaddam, HS; Mohammadi, MR; Momtazmanesh, S, 2020) |
| " Resveratrol dosage was 250 mg twice per day from the beginning of the study." | 2.94 | Resveratrol as adjunctive therapy in treatment of irritability in children with autism: A double-blind and placebo-controlled randomized trial. ( Akhondzadeh, S; Hendouei, F; Mohammadi, MR; Rezaei, F; Sanjari Moghaddam, H; Taslimi, N, 2020) |
| " Drug dosing followed U." | 2.90 | Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial. ( Abramson, RK; Bradley, C; Bragg, JE; Carpenter, LA; Charles, JM; DeVane, CL; Donovan, JL; Geesey, ME; Gwynette, F; Hall, AG; Kinsman, A; Kruesi, MJ; Powers, NR; Raven, S; Sherk, ST; Spratt, E; Stuck, CA; Williams, JE, 2019) |
| "Risperidone-treated 5 to 17 year-old males underwent anthropometric and bone measurements, using dual-energy X-ray absorptiometry and peripheral quantitative computed tomography." | 2.84 | Bone Mass in Boys with Autism Spectrum Disorder. ( Calarge, CA; Schlechte, JA, 2017) |
| "Autism spectrum disorders are a group of neurodevelopmental disorders characterized by impaired verbal and/or nonverbal communication in addition to repeti- tive stereotypical behaviors." | 2.53 | AUTISM IN REVIEW. ( Boustany, RM; Khalifeh, S; Kourtian, S; Yassin, W, 2016) |
| "Therefore, early identification of autism spectrum disorder is important, and experts recommend the use of a validated screening tool at 18- and 24-month well-child visits." | 2.53 | Autism Spectrum Disorder: Primary Care Principles. ( Sanchack, KE; Thomas, CA, 2016) |
| "Because autism spectrum disorder has no cure, selecting the best therapy to manage the disorder is important for therapists, parents, health institutions and researchers with an interest in these types of disorders." | 1.62 | An investigation to choose the proper therapy technique in the management of autism spectrum disorder. ( Albarwary, S; Butler, TA; Mustapha, MT; Ozsahin, DU; Ozsahin, I; Sanlidag, B, 2021) |
| "This short report provides guidance for antipsychotic medication dosing to improve early intervention outcomes." | 1.56 | Early behavioral and developmental interventions in ADNP-syndrome: A case report of SWI/SNF-related neurodevelopmental syndrome. ( Hopkin, R; Pedapati, E; Shillington, A; Suhrie, K, 2020) |
| " We report a boy with autism-spectrum disorder, who developed frequent penile erections after an increase in risperidone dosage for a month." | 1.48 | Frequent Penile Erection in a Boy With Autism-spectrum Disorder: Case Report. ( Bejrananda, T; Thongseiratch, T, 2018) |
| "Risperidone (RIS) is a widely used atypical antipsychotic drug." | 1.43 | Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9-Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders. ( Hongkaew, Y; Limsila, P; Nakorn, CN; Ngamsamut, N; Nuntamool, N; Prommas, S; Puangpetch, A; Sukasem, C; Vanwong, N, 2016) |
| "Autism spectrum disorder is a diagnosis that includes significant social communication deficits/delays along with restricted patterns of interests and behaviors." | 1.43 | Treatment of Autism Spectrum Disorder in Children and Adolescents. ( DeFilippis, M; Wagner, KD, 2016) |
| "These results suggest that hyperprolactinaemia may develop during risperidone treatment." | 1.43 | 9-Hydroxyrisperidone-Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder. ( Chamkrachangpada, B; Hongkaew, Y; Limsila, P; Ngamsamut, N; Puangpetch, A; Srisawasdi, P; Sukasem, C; Tan-Khum, T; Vanwong, N, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 38 (61.29) | 24.3611 |
| 2020's | 24 (38.71) | 2.80 |
| Authors | Studies |
|---|---|
| Fieiras, C | 1 |
| Chen, MH | 1 |
| Escobar Liquitay, CM | 1 |
| Meza, N | 1 |
| Rojas, V | 1 |
| Franco, JVA | 1 |
| Madrid, E | 1 |
| Elnahas, EM | 2 |
| Abuelezz, SA | 1 |
| Mohamad, MI | 1 |
| Nabil, MM | 1 |
| Abdelraouf, SM | 1 |
| Bahaa, N | 1 |
| Hassan, GAM | 1 |
| Aboul-Fotouh, S | 2 |
| Siafis, S | 1 |
| Çıray, O | 1 |
| Wu, H | 1 |
| Schneider-Thoma, J | 1 |
| Bighelli, I | 1 |
| Krause, M | 1 |
| Rodolico, A | 1 |
| Ceraso, A | 1 |
| Deste, G | 1 |
| Huhn, M | 1 |
| Fraguas, D | 1 |
| San José Cáceres, A | 1 |
| Mavridis, D | 1 |
| Charman, T | 1 |
| Murphy, DG | 1 |
| Parellada, M | 2 |
| Arango, C | 2 |
| Leucht, S | 1 |
| Elnaiem, W | 1 |
| Benmelouka, AY | 1 |
| Elgendy, AMN | 1 |
| Abdelgalil, MS | 1 |
| Brimo Alsaman, MZ | 1 |
| Mogheeth, A | 1 |
| Ali, MM | 1 |
| Yousof, SM | 1 |
| Naguy, A | 3 |
| Al-Humoud, AM | 1 |
| Pridmore, S | 2 |
| Abuzeid, MY | 1 |
| Singh, A | 1 |
| Elsori, D | 1 |
| Salazar de Pablo, G | 1 |
| Pastor Jordá, C | 1 |
| Vaquerizo-Serrano, J | 1 |
| Moreno, C | 1 |
| Cabras, A | 1 |
| Hernández, P | 1 |
| Veenstra-VanderWeele, J | 2 |
| Simonoff, E | 1 |
| Fusar-Poli, P | 1 |
| Santosh, P | 1 |
| Cortese, S | 1 |
| Biswas, M | 1 |
| Vanwong, N | 8 |
| Sukasem, C | 8 |
| Lee, A | 1 |
| Choo, H | 1 |
| Jeon, B | 1 |
| Mishra, A | 1 |
| Singla, R | 1 |
| Kumar, R | 1 |
| Sharma, A | 1 |
| Joshi, R | 1 |
| Sarma, P | 1 |
| Kaur, G | 1 |
| Prajapat, M | 1 |
| Bhatia, A | 1 |
| Medhi, B | 1 |
| Jamali, MA | 1 |
| Hasan, AE | 1 |
| Alamiri, B | 1 |
| Karabacak, Y | 1 |
| Barun, S | 1 |
| Vural, İM | 1 |
| Vural, E | 1 |
| Iseri, E | 1 |
| Kahve, AC | 1 |
| Yilmaz, EŞ | 1 |
| Isli, F | 1 |
| Turkes, S | 1 |
| Ezber, E | 1 |
| Paykal, G | 1 |
| Atia, AA | 1 |
| Ashour, RH | 1 |
| Zaki, MM | 1 |
| Rahman, KM | 1 |
| Ramadan, NM | 1 |
| Vandana, P | 1 |
| Simkin, DR | 1 |
| Hendren, RL | 1 |
| Arnold, LE | 5 |
| Ure, A | 1 |
| Cox, GR | 1 |
| Haslam, R | 1 |
| Williams, K | 1 |
| Habib, MZ | 1 |
| Aboul-Ela, YM | 1 |
| Ebeid, MA | 1 |
| Tarek, M | 1 |
| Sadek, DR | 1 |
| Negm, EA | 1 |
| Abdelhakam, DA | 1 |
| Hendouei, F | 1 |
| Sanjari Moghaddam, H | 1 |
| Mohammadi, MR | 3 |
| Taslimi, N | 1 |
| Rezaei, F | 1 |
| Akhondzadeh, S | 3 |
| Shillington, A | 1 |
| Pedapati, E | 1 |
| Hopkin, R | 1 |
| Suhrie, K | 1 |
| Momtazmanesh, S | 1 |
| Amirimoghaddam-Yazdi, Z | 1 |
| Moghaddam, HS | 1 |
| Kloosterboer, SM | 1 |
| de Winter, BCM | 1 |
| Reichart, CG | 1 |
| Kouijzer, MEJ | 1 |
| de Kroon, MMJ | 1 |
| van Daalen, E | 1 |
| Ester, WA | 1 |
| Rieken, R | 1 |
| Dieleman, GC | 1 |
| van Altena, D | 1 |
| Bartelds, B | 1 |
| van Schaik, RHN | 1 |
| Nasserinejad, K | 1 |
| Hillegers, MHJ | 1 |
| van Gelder, T | 1 |
| Dierckx, B | 1 |
| Koch, BCP | 1 |
| Espadas, C | 1 |
| Ballester, P | 1 |
| Londoño, AC | 1 |
| Almenara, S | 1 |
| Aguilar, V | 1 |
| Belda, C | 1 |
| Pérez, E | 1 |
| Peiró, AM | 1 |
| Sharifzadeh, N | 1 |
| Ghasemi, A | 1 |
| Tavakol Afshari, J | 1 |
| Moharari, F | 1 |
| Soltanifar, A | 1 |
| Talaei, A | 1 |
| Pouryousof, HR | 1 |
| Nahidi, M | 1 |
| Fayyazi Bordbar, MR | 1 |
| Ziaee, M | 1 |
| Ozsahin, I | 1 |
| Mustapha, MT | 1 |
| Albarwary, S | 1 |
| Sanlidag, B | 1 |
| Ozsahin, DU | 1 |
| Butler, TA | 1 |
| Faisal, M | 1 |
| Pradeep, V | 1 |
| O'Hanrahan, S | 1 |
| Houghton, R | 1 |
| van den Bergh, J | 1 |
| Law, K | 1 |
| Liu, Y | 1 |
| de Vries, F | 1 |
| Hellings, JA | 1 |
| Han, JC | 1 |
| Calarge, CA | 2 |
| Schlechte, JA | 1 |
| Binici, NC | 1 |
| Güney, SA | 1 |
| Hara, Y | 1 |
| Ago, Y | 1 |
| Taruta, A | 1 |
| Hasebe, S | 1 |
| Kawase, H | 1 |
| Tanabe, W | 1 |
| Tsukada, S | 1 |
| Nakazawa, T | 1 |
| Hashimoto, H | 1 |
| Matsuda, T | 1 |
| Takuma, K | 1 |
| Hajizadeh-Zaker, R | 1 |
| Ghajar, A | 1 |
| Mesgarpour, B | 1 |
| Afarideh, M | 1 |
| Li, A | 1 |
| MacNeill, B | 1 |
| Curiel, H | 1 |
| Poling, A | 1 |
| Srisawasdi, P | 2 |
| Ngamsamut, N | 7 |
| Nuntamool, N | 3 |
| Hongkaew, Y | 7 |
| Puangpetch, A | 7 |
| Chamkrachangpada, B | 2 |
| Limsila, P | 7 |
| Anagnostou, E | 1 |
| Bejrananda, T | 1 |
| Thongseiratch, T | 1 |
| Medhasi, S | 2 |
| Pasomsub, E | 1 |
| Chamnanphon, M | 4 |
| Suthisisang, C | 1 |
| Wilffert, B | 1 |
| Gupta, N | 1 |
| Sachdev, A | 1 |
| Gupta, D | 2 |
| Gupta, S | 1 |
| Nanavati, J | 1 |
| Shafiq, S | 1 |
| Pringsheim, T | 1 |
| Lamy, M | 1 |
| Erickson, CA | 1 |
| Kumar, M | 1 |
| Mattison, R | 1 |
| Baweja, R | 1 |
| Khalifeh, S | 1 |
| Yassin, W | 1 |
| Kourtian, S | 1 |
| Boustany, RM | 1 |
| Frizzell, W | 1 |
| Howard, L | 1 |
| Norris, HC | 1 |
| Chien, J | 1 |
| Schoemakers, RJ | 1 |
| van Kesteren, C | 1 |
| van Rosmalen, J | 1 |
| Eussen, MLJM | 1 |
| Dieleman, HG | 1 |
| Beex-Oosterhuis, MM | 1 |
| Fallah, MS | 1 |
| Shaikh, MR | 1 |
| Neupane, B | 1 |
| Rusiecki, D | 1 |
| Bennett, TA | 1 |
| Beyene, J | 1 |
| DeVane, CL | 1 |
| Charles, JM | 1 |
| Abramson, RK | 1 |
| Williams, JE | 1 |
| Carpenter, LA | 1 |
| Raven, S | 1 |
| Gwynette, F | 1 |
| Stuck, CA | 1 |
| Geesey, ME | 1 |
| Bradley, C | 1 |
| Donovan, JL | 1 |
| Hall, AG | 1 |
| Sherk, ST | 1 |
| Powers, NR | 1 |
| Spratt, E | 1 |
| Kinsman, A | 1 |
| Kruesi, MJ | 1 |
| Bragg, JE | 1 |
| Fusar-Poli, L | 1 |
| Brondino, N | 1 |
| Rocchetti, M | 1 |
| Petrosino, B | 1 |
| Arillotta, D | 1 |
| Damiani, S | 1 |
| Provenzani, U | 1 |
| Petrosino, C | 1 |
| Aguglia, E | 1 |
| Politi, P | 1 |
| Scahill, L | 4 |
| Sukhodolsky, DG | 1 |
| Anderberg, E | 1 |
| Dimitropoulos, A | 1 |
| Dziura, J | 2 |
| Aman, MG | 3 |
| McCracken, J | 1 |
| Tierney, E | 2 |
| Hallett, V | 1 |
| Katz, K | 1 |
| Vitiello, B | 3 |
| McDougle, C | 1 |
| Ziegler, EE | 1 |
| Del Castillo, N | 1 |
| Aman, M | 1 |
| McDougle, CJ | 4 |
| McCracken, JT | 3 |
| Tan-Kam, T | 1 |
| Chamkrachchangpada, B | 1 |
| Sinrachatanant, A | 2 |
| Tan-Khum, T | 1 |
| Cawkwell, P | 1 |
| Lawler, A | 1 |
| Maneta, E | 1 |
| Coffey, BJ | 1 |
| Accordino, RE | 1 |
| Kidd, C | 1 |
| Politte, LC | 1 |
| Henry, CA | 1 |
| Fung, LK | 1 |
| Mahajan, R | 1 |
| Nozzolillo, A | 1 |
| Bernal, P | 1 |
| Krasner, A | 1 |
| Jo, B | 1 |
| Coury, D | 1 |
| Whitaker, A | 1 |
| Hardan, AY | 1 |
| Jeon, S | 1 |
| Boorin, SJ | 1 |
| Caprio, S | 1 |
| Nicol, G | 1 |
| Deng, Y | 1 |
| Challa, SA | 1 |
| Aabbassi, B | 1 |
| Benali, A | 1 |
| Asri, F | 1 |
| Lamberti, M | 1 |
| Siracusano, R | 1 |
| Italiano, D | 1 |
| Alosi, N | 1 |
| Cucinotta, F | 1 |
| Di Rosa, G | 1 |
| Germanò, E | 1 |
| Spina, E | 1 |
| Gagliano, A | 1 |
| Prommas, S | 1 |
| Nakorn, CN | 1 |
| Vo, LC | 1 |
| Snyder, C | 1 |
| McCracken, C | 1 |
| Levi, D | 1 |
| Kelleman, M | 1 |
| Carroll, D | 1 |
| Morrissey, J | 1 |
| DeFilippis, M | 1 |
| Wagner, KD | 1 |
| Sanchack, KE | 1 |
| Thomas, CA | 1 |
| Brown, JT | 1 |
| Eum, S | 1 |
| Cook, EH | 1 |
| Bishop, JR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Biomarkers in Autism of Aripiprazole and Risperidone Treatment[NCT01333072] | Phase 4 | 80 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder[NCT00080145] | 124 participants (Actual) | Interventional | 2004-02-29 | Completed | |||
| The Effectiveness of an Attention-based Intervention for School Aged Autistic Children With Anger Regulating Problems: a Randomized Controlled Trial[NCT05221515] | 51 participants (Actual) | Interventional | 2011-01-01 | Completed | |||
| Effect of PLAY Project Intervention Program on Children With Autism Spectrum Disorder: A Multi-center, Randomized Control Study in China[NCT05531669] | 200 participants (Anticipated) | Interventional | 2022-08-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Multi-center, blinded clinical trial to evaluate biomarkers as predictors of efficacy and safety in children with autistic disorder to risperidone, an atypical antipsychotic drug and aripiprazole, an antipsychotic having a unique clinical and receptor-binding profile.~The major outcome measure was the score on the Irritability subscale of the Aberrant Behavior Checklist (ABC-I) . The ABC has 58 items describing some aspect of behavior and the Irritability sub-scale has 15 items, each completed by a parent or caregiver under the supervision of an investigator. Scores on each item range from 0 = no problem and 3 = severe problem (range of total scores 0 to 45). A fall in scores indicates behavioral improvement." (NCT01333072)
Timeframe: baseline to 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Risperidone | 12.7 |
| Aripiprazole | 14.1 |
19 reviews available for risperidone and Autism Spectrum Disorder
| Article | Year |
|---|---|
Risperidone and aripiprazole for autism spectrum disorder in children: an overview of systematic reviews.
Topics: Aripiprazole; Autism Spectrum Disorder; Child; Humans; Risperidone; Systematic Reviews as Topic | 2023 |
Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.
Topics: Adolescent; Adult; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; H | 2022 |
Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis.
Topics: Anxiety Disorders; Autism Spectrum Disorder; Child; Excitatory Amino Acid Antagonists; Humans; Meman | 2022 |
Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2023 |
Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Humans; Hyperprolactinemia; Pharmacogenetics; Prolac | 2022 |
Serotonin Receptors as Therapeutic Targets for Autism Spectrum Disorder Treatment.
Topics: Aripiprazole; Autism Spectrum Disorder; Child; Humans; Receptors, Serotonin; Risperidone; Serotonin | 2022 |
Autism Spectrum Disorder and Complementary-Integrative Medicine.
Topics: Autism Spectrum Disorder; Autistic Disorder; Child; Humans; Integrative Medicine; Quality of Life; R | 2023 |
Acetylcholinesterase inhibitors for autistic spectrum disorders.
Topics: Acetylcholine; Adolescent; Autism Spectrum Disorder; Child; Child, Preschool; Cholinesterase Inhibit | 2023 |
Dopamine antagonists for treatment resistance in autism spectrum disorders: review and focus on BDNF stimulators loxapine and amitriptyline.
Topics: Adolescent; Adult; Amitriptyline; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Brai | 2017 |
Risperidone in combination with other drugs: Experimental research in individuals with autism spectrum disorder.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Drug Therapy, Combination; Humans | 2017 |
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripipraz | 2018 |
Using antipsychotics for behavioral problems in children.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Autism Spec | 2018 |
Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders.
Topics: Adolescent; Aripiprazole; Autism Spectrum Disorder; Child; Comorbidity; Guidelines as Topic; Humans; | 2018 |
AUTISM IN REVIEW.
Topics: Aripiprazole; Autism Spectrum Disorder; Central Nervous System Agents; Diagnostic and Statistical Ma | 2016 |
Atypical Antipsychotics for Irritability in Pediatric Autism: A Systematic Review and Network Meta-Analysis.
Topics: Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Checklist; Child; Humans; Irritable Mo | 2019 |
Psychopharmacological interventions in autism spectrum disorder.
Topics: Aripiprazole; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Humans; Irrit | 2016 |
Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Child; Child Development D | 2016 |
Autism Spectrum Disorder: Primary Care Principles.
Topics: Antipsychotic Agents; Aripiprazole; Asperger Syndrome; Autism Spectrum Disorder; Autistic Disorder; | 2016 |
Pharmacogenomics of autism spectrum disorder.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Central Nervous System Stimulants; Humans; Pharmacog | 2017 |
10 trials available for risperidone and Autism Spectrum Disorder
| Article | Year |
|---|---|
Resveratrol as adjunctive therapy in treatment of irritability in children with autism: A double-blind and placebo-controlled randomized trial.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Child; Child, Preschool; Double-Blind Method; Drug T | 2020 |
Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled clinical trial.
Topics: Anti-Inflammatory Agents; Antioxidants; Antipsychotic Agents; Autism Spectrum Disorder; Child; Child | 2020 |
Intrathecal autologous bone marrow stem cell therapy in children with autism: A randomized controlled trial.
Topics: Autism Spectrum Disorder; Autistic Disorder; Bone Marrow; Cell- and Tissue-Based Therapy; Child; Hum | 2021 |
Bone Mass in Boys with Autism Spectrum Disorder.
Topics: Absorptiometry, Photon; Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Bone Density; Ch | 2017 |
l-Carnosine As an Adjunctive Therapy to Risperidone in Children with Autistic Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Autistic Disorder; Carnosine; Child; Child, Preschoo | 2018 |
Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Child; Double-Blind Method | 2019 |
Sensitivity of the modified Children's Yale-Brown Obsessive Compulsive Scale to detect change: Results from two multi-site trials.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Child, Preschool; Double-Blind Me | 2016 |
Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Child; Child, Preschool; Female; Humans; Insulin Res | 2016 |
Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2016 |
No Apparent Cardiac Conduction Effects of Acute Treatment with Risperidone in Children with Autism Spectrum Disorder.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Child, Preschool; Double-Blind Me | 2016 |
33 other studies available for risperidone and Autism Spectrum Disorder
| Article | Year |
|---|---|
Novel role of peroxisome proliferator activated receptor-α in valproic acid rat model of autism: Mechanistic study of risperidone and metformin monotherapy versus combination.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Behavior, Animal; Disease Models, Animal; Fema | 2022 |
Low-Dose Risperidone for an Autistic Child with Comorbid ARFID and Misophonia.
Topics: Autism Spectrum Disorder; Autistic Disorder; Avoidant Restrictive Food Intake Disorder; Child; Feedi | 2022 |
Granulocyte Colony-Stimulating Factor Improved Core Symptoms of Autism Spectrum Disorder via Modulating Glutamatergic Receptors in the Prefrontal Cortex and Hippocampus of Rat Brains.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Autism Spectrum Disorder; Brain; | 2022 |
Agomelatine Monotherapy for Autism-A Case Report.
Topics: Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Autistic Disorder; Humans; Risperidone | 2022 |
Profile of psychotropic agents used in autism spectrum disorder according to comorbidities in Turkey: A 4-year evaluation.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Child, Preschool; Humans; Infant; Infant, Newbor | 2023 |
The comparative effectiveness of metformin and risperidone in a rat model of valproic acid-induced autism, Potential role for enhanced autophagy.
Topics: Animals; Autism Spectrum Disorder; Autistic Disorder; Autophagy; Disease Models, Animal; Female; Hum | 2023 |
Risperidone impedes glutamate excitotoxicity in a valproic acid rat model of autism: Role of ADAR2 in AMPA GluA2 RNA editing.
Topics: Adenosine Deaminase; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Autism Spect | 2023 |
Early behavioral and developmental interventions in ADNP-syndrome: A case report of SWI/SNF-related neurodevelopmental syndrome.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Behavioral Symptoms; Child, Preschool; Early Medical | 2020 |
Risperidone plasma concentrations are associated with side effects and effectiveness in children and adolescents with autism spectrum disorder.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Child; Cytochrome P-450 CYP2D6; Humans; | 2021 |
Multimorbidity and psychotropic polypharmacy among participants with autism spectrum disorder with intellectual disability.
Topics: Adult; Autism Spectrum Disorder; Cohort Studies; Comorbidity; Female; Humans; Intellectual Disabilit | 2020 |
An investigation to choose the proper therapy technique in the management of autism spectrum disorder.
Topics: Aripiprazole; Autism Spectrum Disorder; Fuzzy Logic; Humans; Risperidone | 2021 |
Case of paediatric catatonia precipitated by antipsychotic withdrawal in a child with autism spectrum disorder.
Topics: Adolescent; Antipsychotic Agents; Autism Spectrum Disorder; Catatonia; Female; Humans; Lorazepam; Ri | 2021 |
Risperidone versus aripiprazole fracture risk in children and adolescents with autism spectrum disorders.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Child; Cohort Studies; Fem | 2021 |
Epistaxis as an Unexpected Side Effect of Aripiprazole and Risperidone Treatment in Two Children with Two Different Psychiatric Diagnosis.
Topics: Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Autism Spectrum D | 2017 |
Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice.
Topics: Animals; Aripiprazole; Autism Spectrum Disorder; Dendritic Spines; Disease Models, Animal; Dopamine; | 2017 |
Pharmacotherapy of Attention Deficit Hyperactivity Disorder Symptom Profile in ASD.
Topics: Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spect | 2017 |
Pharmacogenetics of Risperidone-Induced Insulin Resistance in Children and Adolescents with Autism Spectrum Disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B; Autism Spect | 2018 |
Frequent Penile Erection in a Boy With Autism-spectrum Disorder: Case Report.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Child; Drug Substitution; Humans; Male; Penile Erect | 2018 |
UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder.
Topics: Age Factors; Autism Spectrum Disorder; Child; Female; Genetic Predisposition to Disease; Glucuronosy | 2018 |
Autism and Allergy - Are They Linked?
Topics: Acetates; Anti-Asthmatic Agents; Antipsychotic Agents; Asthma; Autism Spectrum Disorder; Bronchodila | 2018 |
Withdrawal-Emergent Dyskinesia After Acute Discontinuation of Risperidone in a Child With Autism Spectrum Disorder.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Child; Dyskinesia, Drug-Induced; Humans; Male; Rispe | 2018 |
Homicidal Ideation and Individuals on the Autism Spectrum.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autism Spectrum Disorder; Bup | 2019 |
No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Body Mass Index; Child; Fe | 2019 |
Prevalence and predictors of psychotropic medication use in adolescents and adults with autism spectrum disorder in Italy: A cross-sectional study.
Topics: Adolescent; Adult; Aripiprazole; Autism Spectrum Disorder; Benzodiazepines; Child; Comorbidity; Cros | 2019 |
Iron homeostasis during risperidone treatment in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Autism Spectr | 2015 |
Impact of CYP2D6 Polymorphism on Steady-State Plasma Levels of Risperidone and 9-Hydroxyrisperidone in Thai Children and Adolescents with Autism Spectrum Disorder.
Topics: Alleles; Antipsychotic Agents; Autism Spectrum Disorder; Child; Chromatography, Liquid; Cytochrome P | 2017 |
Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders.
Topics: Adolescent; Autism Spectrum Disorder; Child; Child, Preschool; Cross-Sectional Studies; Cytochrome P | 2016 |
9-Hydroxyrisperidone-Induced Hyperprolactinaemia in Thai Children and Adolescents with Autism Spectrum Disorder.
Topics: Adolescent; Autism Spectrum Disorder; Child; Child, Preschool; Cohort Studies; Dose-Response Relatio | 2016 |
Staying Up at Night: Overlapping Bipolar and Obsessive-Compulsive Disorder Symptoms in an Adolescent with Autism Spectrum Disorder.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autism Spectrum Disorder | 2016 |
Detection of CYP2D6 polymorphism using Luminex xTAG technology in autism spectrum disorder: CYP2D6 activity score and its association with risperidone levels.
Topics: Adolescent; Adult; Autism Spectrum Disorder; Child; Child, Preschool; Cytochrome P-450 CYP2D6; Femal | 2016 |
Risperidone-induced priapism in an autistic child: a case report.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Child; Humans; Male; Morocco; Priapism; Risperidone | 2016 |
Development and Validation of Liquid Chromatography/Tandem Mass Spectrometry Analysis for Therapeutic Drug Monitoring of Risperidone and 9-Hydroxyrisperidone in Pediatric Patients with Autism Spectrum Disorders.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Chromatography, Liquid; Drug Monitoring; Female; Hum | 2016 |
Treatment of Autism Spectrum Disorder in Children and Adolescents.
Topics: Adolescent; Aripiprazole; Autism Spectrum Disorder; Autistic Disorder; Child; Humans; Irritable Mood | 2016 |